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PODIUM SESSION I:
ALTERNATIVE VIEWS IN CANCER OUTCOMES RESEARCH TO COLLECT ALL
BENEFITS
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OBJECTIVES: The impact of new oncology therapies on OS is often assessed by
comparing median OS times in randomised controlled trials. Although this data is
usually available even when many patients remain alive at the end of the trial, the
survival times of those surviving beyond the median point may not be adequately
accounted for in this comparison. In this case study, we discuss the median and the
mean OS using data from a recently published randomised trial. METHODS: Me-
dian OS in the ipilimumab-alone (IPI) and gp100 alone-arms of the trial of IPI in
pre-treated metastatic melanoma (MM) patients (Hodi et al., 2010, NEJM) was com-
pared with non-parametric estimates of mean survival (area under digitised Ka-
plan-Meier survivor function) over four years (maximum follow up 55 months). We
reviewed the methods literature and approaches adopted in relevant assessments.
RESULTS: In this case study, for MM population followed over four years median OS
was reached in the control arm at 6.4 months, and at 10.1 months in the IPI alone
arm, a difference in medians of 3.7 months. Mean OS (area under the curve) over 4
years was 11.5 months in the control arm and 17.6 months in the IPI alone arm, a
difference for IPI of 6.1 months. Though larger than the difference in median OS,
this represents a lower bound on the mean OS benefit over the remaining lifetime,
since the survival benefit was truncated at the end of the trial. CONCLUSIONS:
Mean and median OS both have a place in characterizing OS. In this case study, it
would appear that mean OS may be more informative in describing the potential
benefit of the treatment in patients with MM. Health care decision makers should
consider all the available data when assessing the potential benefits offered by new
therapies in oncology.
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OBJECTIVES: Emerging developments in nanomedicine allow the development
of genome-based technologies for unobtrusive and individualized screening of
colorectal cancer. An example is the nanopill that is currently being developed.
The pill collects gastrointestinal fluid and screens DNA for tumour markers. The
main objective is to inform further development by determining the public
preferences for screening as well as the possible uptake of the nanopill com-
pared to standard CRC screening. METHODS: Data was collected through a dis-
crete choice experiment among individuals aged between 50 and 74 years living in
the The Netherlands and the UK. A full-profile fractional factorial design with a
balanced overlap was implemented. Fourteen random and two fixed choice-tasks
with triplets and dual-none response were used. Through an extensive literature
search following attributes were included: preparation, technique, sensitivity,
specificity, complication rate, and testing frequency. Data were analysed using
Hierarchical Bayes analysis and a Multinomial Logit model. RESULTS: Thirteen
hundred fifty-six respondents completed the questionnaire, from which 884 (65%)
passed the consistency test. Most preferred attributes were: technique (pill), prep-
aration (none); sensitivity (100%), specificity (100%), complications (none), and in-
terval (every 5 years). Nanopill was the most preferred screening modality (46%),
followed by iFOBT (40%), colonoscopy (2%), and sigmoidoscopy (1%). Eleven percent
would choose not to be screened. CONCLUSIONS: CRC screening has been imple-
mented in a number of countries using standard screening techniques, like FOBT
and virtual colonoscopy. However, current developments in nanomedicine allow
the development of new technologies for individualized screening. The expected
benefits delivered by the nanopill are an improved screening adherence, earlier
diagnosis and an increased test performance. The present study suggests the
nanopill to be accepted by the public, which does support further development.
However, the study used hypothetical scenarios to describe the nanopill and the
results do not guarantee market uptake. Cost-benefit analysis and clinical trials
remain mandatory.
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OBJECTIVES: Our aims were to investigate the association between baseline
health-related quality of life (HRQOL) scores of the EORTC QLQ-C30 and survival.
METHODS: We analyzed data from pooled, randomized, controlled trials from Na-
tional Cancer Institute Canada Clinical Trials Group started between 1991 and 2004,
which included survival data from 3635 patients with 8 different cancer sites. So-
ciodemographic variables were sex (men vs. women) and age ( 60 vs.  60), and
clinical variables were WHO performance status (0-1 vs. 2-3) and distant metasta-
ses (no vs. yes). The prognostic significance of sociodemographic and clinical vari-
ables and the 15 QLQ-C30 scales were assessed with Cox proportional hazard mod-
els stratified for cancer site. RESULTS: In the stratified multivariate model
including sociodemographic, clinical, and HRQOL data, the HRQOL parameters of
global QOL/health status (hazard ratio [HR] 1.097, 95% CI 1.05- 1.14; p.0001), phys-
ical function (0.94, 0.897-0.98; p0.0010), dyspnoea (1.04, 1.00-1.07; p0.0120), and
appetite loss (1.06, 1.03-1.09; p.0001) provided significant prognostic information
in addition to the sociodemographic and clinical variables. The gain in predictive
accuracy of prognosis of overall survival of the four HRQOL parameters over the
sociodemographic and clinical characteristics was 3% (Harrell’s C-index for so-
ciodemographic and clinical variables  0.69, and for sociodemographic, clinical,
and HRQOL variables 0.71). The model developed by Quinten et al. 2009 included
pain but this was not found to be statistically significant in our model.
CONCLUSIONS: Our findings suggest that HRQOL scales of the EORTC QLQ-C30
provide prognostic information in addition to that of sociodemographic and clini-
cal measures. This replicates previous findings (Quinten et al., 2009) showing that
HRQOL data can help to predict survival in patients with cancer, although the
specific HRQOL domains that are predictive may vary. The impact of these findings
for clinical management (e.g., in stratification for clinical trials entry or treatment
decision making) need additional study.
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OBJECTIVES: Hepatocellular carcinoma (HCC) is both common and deadly; yet
predicting the future impact of technologies is difficult. We studied opinions about
the potential impact of HCC-control technologies over a 5-10 year horizon and
compared results from Europe and Asia. METHODS: Clinical, policy and patient
advocacy stakeholders were purposively sampled equally from Asia and Europe.
Opinions about eleven possible technologies were studied using best-worst scal-
ing. Here a balanced incomplete block design (BIBD) generated 11 choice tasks
presenting respondents with subsets of five technologies and asking them to as-
sess which might have the most and least impact on HCC control. Assuming se-
quential best-worst choice, respondents’ choices were analyzed using a stratified
conditional logistic regression. Heterogeneity was examined by assessing ordinal
and cardinal properties using Spearman’s Rho and Wald test respectively.
RESULTS: A total of 160 stakeholders (response rate: 46%) completed the survey
and self-identified as having local/regional (30%), national (46%) or international
(24%) influence. Overall, respondents saw molecular targeted therapy (p 0.001)
and early detection (p 0.001) as having most potential, while surgical techniques
(p 0.001) and biopsy-free diagnosis (p 0.001) were viewed negatively. While the
ordinal rankings of technologies were similar (Spearman’s Rho0.81, P0.003),
significant differences were found for some technologies across regions – e.g. in-
terventional radiology was positively valued in Europe (P0.002), but viewed neg-
atively in Asia (P0.118), but adjuvant/neo-adjuvant therapy was viewed positively
in Asia (P0.001), but negatively in Europe (P0.001). CONCLUSIONS: While best-
worst scaling methods are likely to have an important role in informing horizon
scanning and other aspects of health technology assessment, issues of regional
heterogeneity are important to explore. Our results indicated that heterogeneity
may be more important when considering the cardinal values placed on the ele-
ments being examined, as opposed to the ordinal rankings; heterogeneity was not
found for either the best or worst technologies.
PODIUM SESSION I:
NEW APPROACHES FOR EFFECTIVE USE OF DATA: BETTER SYNTHESIS AND
ENHANCED POWER
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TO THE UK PROSPECTIVE DIABETES STUDY (UKPDS) INDIVIDUAL PATIENT
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OBJECTIVES: Within cost effectiveness analysis, joint uncertainty in costs and
effects is commonly dealt with using probabilistic sensitivity analysis (PSA). Al-
though economic models using patient level data can simulate more complex
disease processes than cohort-based models, the computational time required to
eliminate 1st-order uncertainty often makes extensive PSA impossible. To over-
come this, a non-parametric artificial neural network (ANN) simulation meta-mod-
elling method is presented using a case study that evaluates the cost-effectiveness
of intensive blood-glucose monitoring in patients with type 2 diabetes. METHODS:
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